Following the announcement at the annual meeting that this year Compal will transition from a settlement strategy to a predatory strategy, the company has once again presented three main operational axes for the year. These encompass operations, technology, and growth aspects, aiming to further create long-term value for the company through continuous digital project implementation, reinforced AI investments, and strategic positioning.
Compal recorded revenue of NT$77.99 billion in March, an increase of 35.6% month-on-month but a decrease of 2.2% year-on-year. First-quarter revenue stood at NT$199.571 billion, reflecting a 4.7% decline compared to the previous year.
Looking ahead to this year's development, in addition to emphasizing the continuous optimization of product portfolios and the improvement of operational efficiency during the recent earnings conference, Compal announced three major plans during the shareholder's meeting on the 29th. Firstly, on the operational front, the company will continue to introduce digital projects on the basis of automation, undergoing comprehensive intelligent transformation to further strengthen operational resilience.
Regarding technology, particularly AI applications, Compal recognizes the revolutionary impact it will have on the industry. Therefore, Compal's AI layout extends beyond products such as servers, laptops, smartphones, wearable devices, and medical equipment, penetrating into smart production and manufacturing, continuously reinforcing AI investments and strategic positioning. In terms of operations, Compal stated that the five major emerging businesses have established a solid foundation in recent years. In the future, in addition to internal growth, Compal will actively utilize external merger opportunities to accelerate growth momentum. Simultaneously, it will effectively integrate external resources with core corporate capabilities to generate mutual synergies, thereby creating long-term value for the company.
Compal emphasizes that AI, cloud servers, automotive electronics, communication technology, and medical technology are the company's defined five important emerging businesses, for which resources have been allocated and active layout pursued. For example, in the field of medical technology, tangible results are gradually emerging. This includes handheld ultrasound devices from Compal's investment in Potech Biomedical, which have obtained both FDA and TFDA certifications. Additionally, the AI brainwave detector developed by Hongzhi Biomedical aids in the diagnosis and treatment of depression and is currently undergoing clinical trials. Furthermore, Compal's collaboration with Rueifang Hospital in New Taipei City, which will commence construction soon, will integrate sunlight and long-term care services. Upon operation, it will become the actual application field for the company's smart medical products.
Resource (Mandarin):
